Transmission of Quarterly Reports for the Period Ended September 30, 2025

Abbott Laboratories Pakistan LimitedPSX: ABOT

Capital Reserves

Revenue Reserves

Reserve Arising on Merger

General Reserve

Un-appropriated Profit

Oct 30, 2025 at 6:53 AM UTC · Issued by Abbott Laboratories Pakistan Limited

Un-Audited Financial Statements For the Nine months and Three months ended September 30, 2025

Abbott Pakistan

Corporate Information

BOARD OF DIRECTORS

Ehsan Ali Malik (Chairman) (Non-Executive Director)

Syed Anis Ahmed (Chief Executive Officer)

Celestino Jacinto Dos Anjos (Non-Executive Director)

Ayla Majid (Independent Director)

Muhammad Anjum Latif Rana (Non-

Executive Director)*

Seema Khan (Executive Director)

AUDIT COMMITTEE

Mohsin Ali Nathani (Chairman) Ayla Majid

Celestino Jacinto Dos Anjos

HUMAN RESOURCE AND REMUNERATION COMMITTEE

Mohsin Ali Nathani (Chairman) Ehsan Ali Malik

Syed Anis Ahmed

RISK MANAGEMENT COMMITTEE

Ayla Majid (Chairperson) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

SHARE TRANSFER COMMITTEE

Syed Anis Ahmed (Chairman) Celestino Jacinto Dos Anjos Seema Khan

BANKING COMMITTEE

Mohsin Ali Nathani (Chairman) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

NOMINATION COMMITTEE

Ehsan Ali Malik (Chairman) Mohsin Ali Nathani

Syed Anis Ahmed

CHIEF FINANCIAL OFFICER

Syed Tabish Aseem

COMPANY SECRETARY

Muhammad Usama Jamil

Mohsin Ali Nathani (Independent Director) Seema Khan (Executive Director)

AUDIT COMMITTEE

Mohsin Ali Nathani (Chairman) Ayla Majid

Celestino Jacinto Dos Anjos

HUMAN RESOURCE AND REMUNERATION COMMITTEE

Mohsin Ali Nathani (Chairman) Ehsan Ali Malik

Syed Anis Ahmed

RISK MANAGEMENT COMMITTEE

Ayla Majid (Chairperson) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

SHARE TRANSFER COMMITTEE

Syed Anis Ahmed (Chairman) Celestino Jacinto Dos Anjos Seema Khan

BANKING COMMITTEE

Mohsin Ali Nathani (Chairman) Syed Anis Ahmed

Seema Khan

Celestino Jacinto Dos Anjos

NOMINATION COMMITTEE

Ehsan Ali Malik (Chairman) Mohsin Ali Nathani

Syed Anis Ahmed

CHIEF FINANCIAL OFFICER

Syed Tabish Aseem

COMPANY SECRETARY

Muhammad Usama Jamil

CHIEF INTERNAL AUDITOR

Muhammad Ali Shiwani

AUDITORS

EY Ford Rhodes, Chartered Accountants

(a member firm of Ernst & Young Global Limited)

LEGAL ADVISORS

Orr, Dignam & Co. Surridge & Beecheno

BANKERS

Standard Chartered Bank (Pakistan) Limited Deutsche Bank AG

Habib Bank Limited National Bank of Pakistan MCB Bank Limited Faysal Bank Limited Habib Metropolitan Bank Citibank

SENIOR MANAGEMENT TEAM

Syed Anis Ahmed

(Chief Executive Officer) Syed Tabish Aseem (Chief Financial Officer) Moien Ahmed Khan (Director Operations)

Asim Shafiq

(General Manager, Abbott Nutrition International Pakistan)

Saad Siddique

(Country Manager, Abbott Diagnostics Division Pakistan)

Dr. Shaikh Adnan Lateef

(Head of Abbott Diabetes Care Pakistan)

Asghar Huda

(Director Human Resource)

SHARE REGISTRAR

FAMCO Share Registration Services (Pvt) Limited, 8-F, Next to Hotel Faran, Nursery Block 6, P.E.C.H.S, Shahrah-e-Faisal, Karachi.

FACTORY LOCATIONS

Plot No. 258 & 324, Opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi.

Plot No. 13, Sector 20,

*Mr. Muhammad Anjum Latif Rana resigned from his Directorship on the Board with effect from Feb 3rd, 2025.

Korangi Industrial Area, Karachi.

CITY OFFICE CITY OFFICE

8th Floor, Faysal House,

St-02, Shahrah-e-Faisal, Karachi.

11th & 12th Floors

Ocean Tower, G-3, Block 9

Main Clifton Road, Karachi 75600.

P.O. Box 13841

Tel: +92-21-111-Abbott (111-222-688)

SALES OFFICES

House No. 25/III/B, Jamrud Lane, University Town, Peshawar, Pakistan.

House No. 187, Aurangzeb Block, Near Garden Town, Lahore, Pakistan.

WAREHOUSES

Plot No. 136, Street # 9, Sector 1-10/3, Industrial Area, Islamabad.

16 KM Shahpur Kanjran, Multan Road, Lahore.

Hasanabad Gate # 2, Near Pak Arab Fertilizers, Khanewal Road, Multan..

WEBSITE

https://www.pk.abbott

Directors' Report

The Directors are pleased to present the un-audited condensed interim financial statements of your Company, for the nine months ended September 30, 2025, as well as for the third quarter ended September 30, 2025.

FINANCIAL HIGHLIGHTS

For nine months' period ended September 30, 2025

Overall sales increased by 13% over the same period last year. Pharmaceutical sales increased by 16% driven by sustained performance of established brands. Nutritional sales increased by 19% mainly driven by price adjustments, while Diagnostics segment were down by 16% vs. same period last year mainly due to a one-off tender business impact in 2024 sales.

Gross profit margin of your Company during this period improved to 34% vs 28% during the same period last year, mainly driven by price adjustments and various other efficiency measures taken across the Company. Gross margin for the pharmaceutical segment improved to 33% from 29%, whereas the gross margin for Nutritional segment increased to 44% from 35% vs same period last year.

Selling and distribution expenses increased by 19% against the same period last year mainly due to increased marketing and advertisement activities; part of selling and distribution expense is augmented by prior years' inflation adjustments. Net profit as a percentage of sales improved to 10% versus 8% during same period last year.

For third quarter ended September 30, 2025

Sales for the quarter increased by 14% over the same period last year. Pharmaceutical as well as nutrition sales increased by 16%.

Similar to the year-to-date results, gross profit margin of the Company improved to 34% from 33% during the same period last year on account of reasons mentioned above.

Operating expenses increased by 22% over the same period last year on account of higher sales promotion and forwarding expenses. Other charges increased by PKR 180 million over the same period last year due to increase in statutory charges in line with improved profitability.

FUTURE OUTLOOK

The pharmaceutical and healthcare landscape continues to show signs of resilience amid a gradually stabilizing macroeconomic environment. The Company's year-to-date performance, marked by double-digit growth in core segments and improved profitability, reflects the effectiveness of strategic actions and marketing initiatives.

Looking ahead, the sector's trajectory will depend on sustained regulatory reforms, particularly in pricing mechanisms for essential medicines, and continued fiscal discipline. While inflationary pressures and statutory cost escalations remain key challenges, your Company is well-positioned to navigate these through disciplined cost management and portfolio optimization.

With a focus on innovation, patient-centric solutions, and operational agility, your Company remains committed to deliver sustainable value to its stakeholders.

Syed Anis Ahmed Ehsan Ali Malik

Chief Executive Director

Karachi: October 29th 2025

Abbott Pakistan

ٹروپر ز/ٹ ی sئ اڈ

ہ ی پ ی ی

یلاو ےنوہ متخ وک 2025ربمتس 30 ھتاس ھتاس ےک یہام ونش یلاو ےنوہ متخ وک 2025 ربمتس 30 ےکغ ینپمک یک پآ ز/ٹ ی sئ اڈت ۔�ی ےترک سوسحم یشوخ ےئوہ ےترک � ےراوشوگ یلام یروبع ہدش ٹڈآ� لی ےک یہام ہس ی�

ں�یی�ککلھجج� یلام

غ غ ٹ

غ کئئ غ یی یہام ون یلاو ےنوہ متخ وک 2025 ربمتس 30

ت 1غ 6 غ ت غ غ 13غ غ ش غ ٹ غ

غ ی 19 ٹ غ ٹ س غ ئ ٹ

یک سج اوہ ہفاضا Pی می سی pی سی امراف ۔اوہ ہفاضا Pی می سی می ےلباقم ےک تدم یسا یک لاس ہتشزگ می ں��می�ق رپ روط ید�ج وج اوہ ہفاضا Pی می �و) یک /ی رٹsی ےہ یگدرکراک لسلسم یک ز�اsج مئاق ےس ہجو

عقاو یمک Pی 16 می ےلباقم ےک ےصرع یسا ےک لاس ش ہتشزگ مغ ی ٹ �غ ٹ �مگی�س سک� ��گ�اڈ ہکبج ےہ ےس ہجوغ یک ٹنمٹسج�ی ا

۔اھت sا اک سنsج ر�ی ہف�طیک� می 2024 ہجو ید�ی ج یک سج ،یئوہ

ی ٹ ی ی

غ غ ش ی غ ٹ ٹ

28 ٹ ت غ غ

ھٹsج ےس Pی غ می ےلباقم ےک تدم یسا یک لاس ےلھچپ نجرام اک عفانم یعومجم ےک ینپمک یک پآ نارود ےک تدم سا تامادقا ےک یگدرکراک �ی د فلتخم ےئگغ ےئاھٹا می ینپمک یروپغ روا ٹنمٹسج�ی ا می ں��می�ق رپ روط ید�ی ج وج ،گی وہ Pی 34 رک ےک ےقبط ےک/رٹsی ہکبج ،گی وہ Pغ ی 33 رک ھsج ےس Pغ ی 29 نجرام یعومجم لی ےک ہقبط pی سی امراف ۔ ےہ ےس ہجو یک

۔گی وہ P 44 رک ھsج ےس P 35 م ےلباقم ےک تدم یسا یک لاس ےلھچپ نجرام یعومجم لی

غ ج ی غ ی

ی غ ی ت ت

ت غ غ

غ ت غ غ غ ٹ

ی ی غ ی ٹ ٹ

ہجو ید�ی یک سج ،اوہ ہفاضا P 19 م ےلباقم ےک تےصت رع یسا ےک لاس ہتشزگ م تاجا�ا ےک � روا �و) یک یئاگنہم یک ںولاس ہتشزگ ہصح �ی ا اک تغاجا�ا ےک �ی روا �و) ؛ےہ ہفاضا می ںمی رگرس یراہتشا روا گ��ی کرام م ےصرع یسا لاس ہتشزگ ہکبج گی وہ P 10 رک وہ رتہب ،ےس سج انت ےک س ،عفانم صلاخ ۔ےہ اھsج ےس ٹنمٹسجغ �ی ا ۔اھت Pی 8 �ی

ئئ تت

ٹ غ غ کیی یہام ہس ی�یی یلاو ےنوہ متخ وک 2025 ربمتس 30

ھتاس ھتاس ےک pی سی امراف ۔اوہ ہفاضا Pی 14 می سی لی ےک یہام ہس می ےلباقمی غ ےک تدمی یست اغ یکغ لاسغ غ ہتشیش زگغ

۔اوہ ہفاضا P 16 م �و) یک /رٹsی

می تدم یسا یک لاس ہتشزگ نجرام اک عفانم یعومجم ےک ینپمکرپ ءانب یک تاہوجو ہروکذم حرط یکغ جئاتن ےک �ت با ےکغ لاس ۔گی وہ Pی 34 رک ھsج ےس Pی 33

غ غ

نشومورپ غسی ہجو ید�ی غ ج یک سج ،اوہ ہفاضا Pی غ 22 می ےلباقم ےک ےصرع یسا ےک لاس ہتشزگ می تاجا�غ ا �غ ٹ ی رپآ ۔ےہ ہفاضا می تاجا�ا �ڈروراف روا

۔ےہ عش ج� ےک ےفاضا می �غ ج راچ ینوناق ےس ہجو یک عفانم رتہب ہک وج ،اوہ ہفاضا اک ےپور لمغ ی 180 می �غ ج راچ �ی د

ش ج ی

ہم�غغ رظنم اکٹ لبقتسم

ینپمک ۔�ی ہ ں�ی امن ر�آ ےک یطغوبضمغ نارود ےک میاکحتسا �ردتب ےکت تالاح یشاعمی ہدوجوم می غےبعشج ےک تحص روا pی سی امراف

ت ج ش ش غ ٹ ی

یترک یساکع یک تج� سا ،ےہ �ی م ےس یرتہب م عفانم روا یقs یسدنہ ود م ںوبعش ید�ی وج ،یگدرکراک لاس ہب لاس یک ۔�ی ہ ےئوہ �� sؤم تامادقا گ��کرام روا یلمع تمکحِ یک سا ہک ےہ

ےک ں��می�قغ یک�غ لی��پت�ی ودا یرورض رپ روط صغ اخ ،اگوہ رپ تاحالصا یلٹ ی �ی ر لقتسم راصحنا اک تمس یک ےبعش سا ،لی ےک ہدنئغ آ�ت

پی آ ،غ�شیی ہ �ج� مہا ہفاضا می تاجا�ای ینوناق روا ؤج�د ےک یئاگنہم ہچرگات ۔رپ لسلستش ےک طبض و مظن یلام روا ماظن ےک �ی �ع

م �زوپ یھچا �ی رذ ےک یرتہب یک لوف ٹروپ روا قسن و مظن ےک گال sؤم لی ےک ےنٹمن ےس لئاسم نا ینپمک یک ۔ےہ

ئ ٹ غ ش ی غ

�ٹ ی �غ ی ا �غ ی پ

/ٹ ی sئ اڈ

ردق را�ی پ� وک زرڈلوہ کی ��سا ےنپا ینپمک یک پآ ،ھتاس ےک ہجوت رپ یتسچ �رپآ روا ،لح زوکرم رپ �ی رم ،یزارط ت�ج غ ۔ےہ مزعرپ لی ےک ےنرک مہا)

ء 2025sج وتکا 29 :یچارک

Condensed Interim Statement of

Financial Position

As at September 30, 2025

September 30, December 31,

2025			2024
Note ------- Rupees in '000 ------- (Un-audited) (Audited)
ASSETS NON-CURRENT ASSETS
Property, plant and equipment	6	14,702,339		14,252,797
Intangible assets		884		1,250
Long-term loans and advances		129,237		114,226
Long-term deposits		32,713		7,513
Long-term prepayments		10,078		13,710
		14,875,251		14,389,496
CURRENT ASSETS
Stores and spares		570,438		529,619
Stock-in-trade	7	13,517,073		10,694,515
Trade debts		3,390,553		2,982,679
Loans and advances	8	1,047,173		938,021
Trade deposits and short-term prepayments	9	555,581		283,813
Other receivables	10	1,330,418		1,182,530
Taxation - net		240,470		468,136
Cash and cash equivalents	11	9,009,546		6,182,349
		29,661,252		23,261,662
TOTAL ASSETS		44,536,503		37,651,158
EQUITY AND LIABILITIES SHARE CAPITAL AND RESERVES
Authorised capital 200,000,000 ordinary shares of Rs.10 each		2,000,000		2,000,000
Issued, subscribed and paid-up capital Reserves	12	979,003		979,003
- Capital		1,993,957		1,750,481
- Revenue		25,381,867		20,995,152
		27,375,824		22,745,633
NON-CURRENT LIABILITIES		28,354,827		23,724,636
Deferred taxation - net		869,361		1,052,587
Staff retirement benefits		1,230,791		1,184,179
Lease liabilities		349,206		29,545
		2,449,358		2,266,311
CURRENT LIABILITIES
Trade and other payables	13	12,681,033		10,951,662
Unclaimed dividends		71,605		63,715
Unpaid dividends		209,714		-
Current maturity of lease liabilities		85,873		22,683
Provisions		684,093		622,151
		13,732,318		11,660,211
CONTINGENCIES AND COMMITMENTS TOTAL EQUITY AND LIABILITIES	14	44,536,503		37,651,158

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Director

Chief Executive Officer

Chief Financial Officer

Condensed Interim Statement of Profit or Loss (Un-Audited)

For the nine months and three months ended September 30, 2025

Nine Months Ended Three Months Ended

September 30,

2025

September 30,

2024

September 30,

2025

September 30,

2024

Note Rupees in '000

(8,501,410)	(7,120,361)	(2,974,143)	(2,404,851)
(972,482)	(857,385)	(334,287)	(300,482)
(1,256,699)	(578,954)	(430,365)	(250,259)
603,335	541,111	186,590	83,003

SALES - NET

Local		53,909,372		47,273,134		18,995,527		16,784,001
Export		2,317,551		2,290,945		823,607		580,545
		56,226,923		49,564,079		19,819,134		17,364,546
Cost of sales		(36,886,086)		(35,493,642)		(13,093,197)		(11,634,162)
GROSS PROFIT		19,340,837		14,070,437		6,725,937		5,730,384
Selling and distribution expenses
Administrative expenses
Other charges	15
Other income	16
		(10,127,256)		(8,015,589)		(3,552,205)		(2,872,589)
		9,213,581		6,054,848		3,173,732		2,857,795
Finance costs		(55,363)		(18,587)		(17,659)		(5,988)
PROFIT BEFORE TAXATION		9,158,218		6,036,261		3,156,073		2,851,807
Minimum tax differential		(146,989)		(87,306)		(146,989)		79,576
		9,011,229		5,948,955		3,009,084		2,931,383
INCOME TAX
Current - For the year
- Prior year
Deferred
(3,645,511)				(1,999,672)		(1,186,538)		(1,122,240)
NET PROFIT FOR THE PERIOD 5,365,718				3,949,283		1,822,546		1,809,143
BASIC AND DILUTED EARNINGS PER
SHARE (Rs. per share)		54.81	40.34		18.62		18.48

(3,828,736)	(1,913,620)	(1,181,163)	(1,182,528)
-	32,253	-	32,253
183,225	(118,305)	(5,375)	28,035

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Director

Chief Executive Officer Chief Financial Officer

Condensed Interim Statement of Comprehensive Income (Un-Audited)

For the nine months and three months ended September 30, 2025

Nine Months Ended Three Months Ended

September 30,

2025

September 30,

2024

September 30,

2025

September 30,

2024

Rupees in '000

Profit for the period	5,365,718	3,949,283	1,822,546	1,809,143
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	5,365,718	3,949,283	1,822,546	1,809,143

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Director

Chief Executive Officer Chief Financial Officer

Condensed Interim Statement of Cash Flows (Un-Audited)

For the nine months ended September 30, 2025

September 30, September 30,

2025 2024

Note ------- Rupees in '000 -------

CASH FLOWS FROM OPERATING ACTIVITIES
Cash generated from operations	17	9,020,548	4,136,473
Income tax paid		(3,748,060)	(2,411,024)
Long-term loans and advances - net		(15,011)	(12,953)
Long-term deposits - net		(25,200)	-
Long-term prepayments - net		3,632	(10,416)
Contributions to staff retirement benefit funds		(253,147)	(218,923)
Net movement in provisions		61,942	-
Net cash inflow from operating activities		5,044,704	1,483,157
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to operating fixed assets and CWIP Sale proceeds from disposal of property, plant and	6.1	(1,893,111) 177,968	(1,925,266) 85,500
equipment Interest income		345,737	329,970
Net cash outflow from investing activities		(1,369,406)	(1,509,796)
CASH FLOWS FROM FINANCING ACTIVITIES
Finance costs paid		(7,571)	(8,811)
Lease rentals paid		(79,131)	(117,729)
Dividends paid		(761,399)	(1,030,325)
Net cash outflow from financing activities		(848,101)	(1,156,865)
NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS		2,827,197	(1,183,504)

	6,182,349		5,036,712
17.2	9,009,546		3,853,208

CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD

CASH AND CASH EQUIVALENTS AT END OF THE PERIOD

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Director

Chief Executive Officer Chief Financial Officer

Condensed Interim Statement of Changes in Equity (Un-Audited)

For the nine months ended September 30, 2025

Share Capital

Total Equity

Balance as at January 1, 2024 (Audited) 979,003 Transactions with owners, recorded directly in equity	46,097		1,391,065	5,338,422		10,482,759	17,258,343		18,237,346
Employee benefit cost under IFRS 2- 'Share based - Total comprehensive income for the period ended September 30, 2024	-		244,953	-		-	244,953		244,953
Net profit for the period -
Other comprehensive income for the period -
-		-	-		-	3,949,283		3,949,283	3,949,283
Balance as at September 30, 2024 (Un-audited) 979,003		46,097	1,636,018		5,338,422	14,432,042		21,452,579	22,431,582
Balance as at January 01, 2025 (Audited) 979,003		46,097	1,704,384		5,338,422	15,656,730		22,745,633	23,724,636
Final dividend for the year ended December 31, 2024 @ Rs. 10/- per share -		-	-		-	(979,003)		(979,003)	(979,003)
Employee benefit cost under IFRS 2- 'Share based - Total comprehensive income for the period ended		-	243,476		-	-		243,476	243,476

Rupees in '000

payments'

- -	3,949,283 -

3,949,283

payments'

September 30, 2025
Net profit for the period	-	-	-	-	5,365,718	5,365,718	5,365,718
Other comprehensive income for the period	-	-	-	-	-	-	-
	-	-	-	-	5,365,718	5,365,718	5,365,718
Balance as at September 30, 2025 (Un-audited)	979,003	46,097	1,947,860	5,338,422	20,043,445	27,375,824	28,354,827

The annexed notes 1 to 20 form an integral part of these condensed interim financial statements.

Director

Chief Executive Officer

Chief Financial Officer

THE COMPANY AND ITS OPERATIONS
Abbott Laboratories (Pakistan) Limited (the Company) is a public limited Company incorporated in Pakistan on July 02, 1948, and its shares are quoted on Pakistan Stock Exchange. The address of its registered office is Plot No. 258 & 324, opposite Radio Pakistan Transmission Centre, Hyderabad Road, Landhi, Karachi. The Company is principally engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital and consumer products.
STATEMENT OF COMPLIANCE
These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting which comprise of International Accounting Standard (IAS) 34 - 'Interim Financial Reporting', issued by the International Accounting Standards Board (IASB) as notified under the Companies Act, 2017 and provisions of and directives issued under the Companies Act, 2017. Where the provisions of and directives issued under the Companies Act, 2017 differ with the requirements of IAS 34, the provisions of and directives issued under the Companies Act, 2017 have been followed.
BASIS OF PREPARATION
These condensed interim financial statements have been prepared in accordance with the accounting and reporting standards as applicable in Pakistan for interim financial reporting and notified under the Companies Act, 2017 and provisions of and directives issued under the Companies Act, 2017. These condensed interim financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the annual financial statements of the Company for the year ended December 31, 2024.
These condensed interim financial statements are presented in Pakistan Rupees, which is the Company's functional and presentation currency.
NEW STANDARDS, INTERPRETATIONS AND AMENDMENTS TO INTERNATIONAL FINANCIAL REPORTING STANDARDS
There are certain amendments to existing accounting and reporting standards that have become applicable to the Company for accounting periods beginning on or after January 01, 2025. These are either considered to not be relevant or do not have any significant impact and accordingly, have not been detailed in these condensed interim financial statements.
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND FINANCIAL RISK MANAGEMENT
The preparation of condensed interim financial statements in conformity with approved accounting standards requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company's accounting policies. Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognised in the period in which the estimate is revised and in any future periods affected.
Judgements and estimates made by the management in the preparation of these condensed interim financial statements are the same as those applied in the Company's annual financial statements for the year ended December 31, 2024.
The Company's financial risk management objectives and policies are consistent with those disclosed in the annual financial statements as at and for the year ended December 31, 2024.
September 30, December 31,
2025 2024
Note ---- Rupees in '000 ----
(Un-audited) (Audited)

PROPERTY, PLANT AND EQUIPMENT

Operating fixed assets 6.1 & 6.2 12,806,815 11,329,199

Capital work-in-progress 6.1 1,511,223 2,858,741

Right-of-use assets 6.3 384,301 64,857

14,702,339 14,252,797

Following were the additions and disposals of operating fixed assets and capital work-in-progress during the period:

Additions Disposals

Cost Cost Accumulated Depreciation

Rupees in '000

Plant and machinery	2,669,178	6,059	4,949
Vehicles	368,286	124,209	73,064
Office equipment	-	287	272
Computers	148,040	-	-
Service equipment	55,125	64,775	38,865

Capital work-in-progress - net of transfers (1,347,518) - -

1,893,111 195,330 117,150

Depreciation charge for the period ended September 30, 2025 amounting to Rs. 1,684.833 million (September 30, 2024: Rs. 1,254.010 million).
Right-of-use assets
September 30, December 31,
2025 2024
Note ---- Rupees in '000 ----
(Un-audited) (Audited)
Warehouses, sales offices and city office 6.3.1 384,301 64,857
1. Depreciation charge for the period ended September 30, 2025 amounted to Rs. 94.746 million (September 30, 2024: Rs. 63.165 million).

7.	STOCK-IN-TRADE	September 30, 2025	December 31, 2024
Note ---- Rupees in '000 ----
		(Un-audited)	(Audited)
Raw and packing materials [including stock-in-transit of Rs. 1,613.065 million (December 31, 2024: Rs. 1,312.217 million)		6,264,558	6,026,056
Work-in-process		801,631	611,605
Finished goods [including stock-in-transit of Rs.
	1,062.346 million (December 31, 2024: Rs.
426.328 million)]		7.1	6,973,843	4,439,354
		14,040,032		11,077,015
Less: provision for slow moving and obsolete items		(522,959)		(382,500)
		13,517,073		10,694,515

7.1 Stock-in-trade includes items costing Rs. 1,018.365 million (December 31, 2024: Rs. 875.646 million) valued at net realisable value of Rs. 753.033 million (December 31, 2024: Rs. 739.761 million) resulting in a write down of Rs. 265.332 million (December 31, 2024: Rs. 135.885 million)

LOANS AND ADVANCES
Represent loans and advances amounted to Rs. 60.530 million and Rs. 986.643 million (December 31, 2024: Rs. 52.451 million and Rs. 885.570 million), respectively, net of allowance.
TRADE DEPOSITS AND SHORT-TERM PREPAYMENTS
Represent trade deposits and short-term prepayments amounted to Rs. 361.014 million and Rs. 194.567 million (December 31, 2024: Rs. 190.395 million and Rs. 93.418 million), respectively, net of allowance.
OTHER RECEIVABLES
Includes sales tax receivable and due from related parties amounting to Rs. 657.165 million and Rs. 194.364 million (December 31, 2024: Rs. 656.551 million and Rs. 303.825 million), respectively.
September 30, December 31,
2025 2024
Note ---- Rupees in '000 ----
(Un-audited) (Audited)

CASH AND BANK BALANCES

With banks

Saving accounts:

- local currency 11.1 7,278,437 4,610,252

Current accounts:

local currency
foreign currency
In hand
local currency
foreign currency

93,647	17,532
1,631,797	1,548,539

1,725,444 1,566,071

1,138	4,531
4,527	1,495

5,665 6,026

9,009,546 6,182,349

These saving accounts carry mark-up at the rate of 5% to 10.50% (December 31, 2024:
6.50% to 13.50%) per annum.

ISSUED, SUBSCRIBED AND PAID-UP CAPITAL
As at September 30, 2024, Abbott Asia Investments Limited, UK (the Holding Company) held 76,259,454 (December 31, 2024: 76,259,454) shares. The ultimate holding company is Abbott Laboratories, USA.
TRADE AND OTHER PAYABLES
Includes accrued liabilities amounted to Rs. 6,926.847 million (December 31, 2024: Rs. 5,344.592 million), bills payable of Rs. 3,065.791 million (December 31, 2024: Rs.
2,704.992 million).
CONTINGENCIES AND COMMITMENTS
1. The Company is defending various minor suits filed against it in various courts in Pakistan related to its business operations as at reporting date, which are not material to disclose as contingencies. The Company's management is confident, based on the advice of its legal advisors, that these suits will be decided in the Company's favour.
2. Commitments
  1. Commitments for capital expenditure as at September 30, 2025, aggregated to Rs. 739.952 million (December 31, 2024: Rs. 802.658 million).
  2. Commitments in respect of letters of credit as at September 30, 2025 aggregated to Rs.1,666.646 million (December 31, 2024: Rs. 1,603.211 million).
  3. The Company has given bank guarantees as at September 30, 2024 of Rs. 991.002 million (December 31, 2024: 827.108 million) to the Customs Department, a utility company and other institutions against tenders.
  4. The Company has obtained short-term financing facilities from various commercial banks amounting to Rs. 7,600 million (December 31, 2024: Rs. 6,600 million). These facilities can be utilised for letters of credit, guarantees and running finance / short-term loans. However, the running finance / short-term loan utilisation cannot exceed Rs. 3,290 million (December 31, 2024: Rs. 3,290 million). The running finance / short-term loan carries mark-up at rates ranging from KIBOR minus 0.25% to flat KIBOR (December 31, 2024: KIBOR minus 0.25% to flat KIBOR) per annum and are secured against first joint pari passu hypothecation charge over stocks and book debts of the Company, ranking hypothecation charge over stocks and book debts of the Company, promissory notes, and counter guarantees. The Company has not utilised any amount against running finance / short-term loan facilities neither pledged its inventory at the statement of financial position date.
OTHER CHARGES